Traction for sustainable healthcare plastics
BIOVOX successfully closes €2.2 million seed round
BIOVOX GmbH, the Darmstadt, Germany-based company pioneering sustainable bioplastics for medical applications, announced the successful closing of its €2.2 million seed round. The round was led by High-Tech Gründerfonds (HTGF) with significant participation from Beteiligungs-Managementgesellschaft Hessen mbH (BMH) and a group of existing and new investors including Auxxo, Otto Braun, Petra Wörwag and Katharina Klohe as well members of the business angel club better ventures and Business Angels FrankfurtRheinMain. The investment will enable BIOVOX to accelerate the development and production of its portfolio of innovative bioplastic solutions designed to revolutionise the healthcare industry.
Transforming healthcare towards sustainability
The healthcare sector is – with 4.4% – a major contributor to global greenhouse gas emissions, with plastics in healthcare alone responsible for carbon emissions comparable to the total emissions of a Sweden or Denmark. Sterile single use medical products are essential for maintaining high hygiene standards and availability at a reasonable price point, yet healthcare cannot continue with the linear economy based on fossil resources, overstepping the boundaries of a healthy planet and therefore leading to more health problems in the long run.
BIOVOX is addressing this critical issue of a high-carbon linear economy in healthcare by having developed the world’s first sustainable medical-grade bioplastics for devices and packaging. The company produces and supplies biocompatible and sustainable plastics that meet the highest regulatory standards of today and tomorrow.
These innovative materials are bio-based, tested for biocompatibility, were developed and manufactured under BIOVOX’ ISO 13485-certified medical quality management system, and reduce the lifecycle carbon footprint by 50 to 85% compared to conventional virgin fossil plastics. BIOVOX’s line of bioplastics is designed for a wide range of medical, pharmaceutical and laboratory applications, including consumables, disposables, packaging, surgical instruments, and endoscopy devices. The materials meet the most stringent regulatory standards, ensuring high quality and patient safety.
Founded in 2021, BIOVOX is at the forefront of the sustainable healthcare market, setting the standard for bioplastic compounds made from renewable resources. More than 50 customers, including many segment leaders in medical devices, are working with BIOVOX to develop green healthcare solutions. One customer has already launched its first product using BIOVOX materials.
The newly secured funding enables BIOVOX headed by founders and mechanical engineers CEO Julian Lotz, CTO Vinzenz Nienhaus and COO Carmen Rommel to scale operations by establishing a proprietary technical centre and to expand the sales and customer success team.
"With the support of our new and existing investors, we will scale the organisation to cater to all the customers currently waiting for our sustainable materials. Our pioneering products have already created a strong brand and a rich pipeline. Now we have the financial means to support our customers even better in developing a more environment friendly product range ready for the circular economy. Let’s create full traction for sustainable healthcare plastics", Dr.-Ing. Julian Lotz, CEO of BIOVOX GmbH.
"With BIOVOX, we are funding a team of visionaries whose technological brilliance and deep understanding of regulatory affairs are revolutionising the development of sustainable plastics for the life sciences industry. Not only do they speak the customers’ language, but they have validated their solutions through numerous successful pilot projects and have already brought a product to market. Their contribution to reducing the carbon footprint in healthcare will be immense and we at HTGF are proud to support such a technology for a better environment and make it commercially successful", Tilmann Petersen, Investment Manager at HTGF.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Proteomics can improve breast cancer treatment
Latte lovers rejoice! Drinking coffee could lower the risk of Alzheimer’s disease - Drinking more coffee gave positive results in relation to certain domains of cognitive function
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment
Infection with stomach bacteria may increase risk of Alzheimer's disease - Helicobacter pylori enters the central nervous system
Messe München International takes over one of India's leading trade fairs for laboratory technology
Melatonin boost a key to fighting breast cancer
Alentis Therapeutics Raises USD 67 Million in Series B Financing - Funding to Advance Pipeline of Anti-fibrotic Molecules into the Clinic
Key advance toward production of important biofuel - MOF can efficiently separate biobutanol from the fermentation broth
Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis - Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF
Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
Fruit peels for cleaning wastewater - Wastewater cleaned thanks to a new adsorbent material made from fruit peels
